Literature DB >> 17177135

Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects.

L Li1, G Yang, Q Li, Y Tang, M Yang, H Yang, K Li.   

Abstract

Visfatin and apelin are two novel adipocyte- secreted hormone proposed to link obesity with insulin resistance. In this study we investigated whether plasma visfatin and apelin levels were altered in normal, impaired glucose tolerance, and type 2 diabetic subjects. We also assessed the association between plasma visfatin, or apelin and body composition, metabolic parameters, and resistin concentrations in these subjects. The visfatin levels of fasting and 2-h post-glucose load were found to be significantly decreased in diabetics compared with the controls ( P<0.05). In contrast, basal apelin levels were significantly increased in the IGT and diabetic subjects compared with the controls ( P<0.05 and P<0.01). The apelin levels of 2-h post-glucose load were significantly higher than the basal levels in every group (all P<0.05). Fasting plasma visfatin was found to correlate positively and significantly with BMI, WHR, and fasting plasma resistin, but negatively with HbA1c and 2 h OGTT glucose. Multiple regression analysis showed that WHR, HbA1c, 2 h OGTT glucose were independent related factors influencing plasma visfatin levels. Fasting plasma apelin levels correlated positively with HOMA-IR, BMI, TC, LDL-C, FBG and Fasting plasma insulin. Multiple regression analysis also showed that HOMA-IR, BMI, and TC were independent related factors influencing plasma apelin levels. The present work indicates the potential link of visfatin and apelin with the pathogenesis of insulin resistance and T2DM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17177135     DOI: 10.1055/s-2006-948309

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  66 in total

Review 1.  Apelin and insulin resistance: another arrow for the quiver?

Authors:  Shiming Xu; Philip S Tsao; Patrick Yue
Journal:  J Diabetes       Date:  2011-09       Impact factor: 4.006

Review 2.  The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders.

Authors:  Eric Marsault; Catherine Llorens-Cortes; Xavier Iturrioz; Hyung J Chun; Olivier Lesur; Gavin Y Oudit; Mannix Auger-Messier
Journal:  Ann N Y Acad Sci       Date:  2019-06-25       Impact factor: 5.691

3.  Apelin decreases lipolysis via G(q), G(i), and AMPK-Dependent Mechanisms.

Authors:  Patrick Yue; Hong Jin; Shiming Xu; Marissa Aillaud; Alicia C Deng; Junya Azuma; Ramendra K Kundu; Gerald M Reaven; Thomas Quertermous; Philip S Tsao
Journal:  Endocrinology       Date:  2010-11-03       Impact factor: 4.736

Review 4.  Apelin, diabetes, and obesity.

Authors:  Isabelle Castan-Laurell; Cédric Dray; Camille Attané; Thibaut Duparc; Claude Knauf; Philippe Valet
Journal:  Endocrine       Date:  2011-08       Impact factor: 3.633

5.  HIF-1 regulates hypoxia- and insulin-induced expression of apelin in adipocytes.

Authors:  Alexander J Glassford; Patrick Yue; Ahmad Y Sheikh; Hyung J Chun; Shirin Zarafshar; Denise A Chan; Gerald M Reaven; Thomas Quertermous; Philip S Tsao
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-09-18       Impact factor: 4.310

6.  Increased bone mass in mice lacking the adipokine apelin.

Authors:  Lalita Wattanachanya; Wei-Dar Lu; Ramendra K Kundu; Liping Wang; Marcia J Abbott; Dylan O'Carroll; Thomas Quertermous; Robert A Nissenson
Journal:  Endocrinology       Date:  2013-04-12       Impact factor: 4.736

7.  Endothelial APLNR regulates tissue fatty acid uptake and is essential for apelin's glucose-lowering effects.

Authors:  Cheol Hwangbo; Jingxia Wu; Irinna Papangeli; Takaomi Adachi; Bikram Sharma; Saejeong Park; Lina Zhao; Hyekyung Ju; Gwang-Woong Go; Guoliang Cui; Mohammed Inayathullah; Judith K Job; Jayakumar Rajadas; Stephanie L Kwei; Ming O Li; Alan R Morrison; Thomas Quertermous; Arya Mani; Kristy Red-Horse; Hyung J Chun
Journal:  Sci Transl Med       Date:  2017-09-13       Impact factor: 17.956

8.  Maternal visfatin concentration in normal pregnancy.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Juan Pedro Kusanovic; Edi Vaisbuch; Offer Erez; Nandor Gabor Than; Tinnakorn Chaiworapongsa; Chia-Ling Nhan-Chang; Percy Pacora; Francesca Gotsch; Lami Yeo; Sun Kwon Kim; Samuel S Edwin; Sonia S Hassan; Pooja Mittal
Journal:  J Perinat Med       Date:  2009       Impact factor: 1.901

9.  The increase in serum visfatin after bariatric surgery in morbidly obese women is modulated by weight loss, waist circumference, and presence or absence of diabetes before surgery.

Authors:  José I Botella-Carretero; Manuel Luque-Ramírez; Francisco Alvarez-Blasco; Roberto Peromingo; José L San Millán; Héctor F Escobar-Morreale
Journal:  Obes Surg       Date:  2008-03-19       Impact factor: 4.129

10.  Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester.

Authors:  M Akturk; A E Altinova; I Mert; U Buyukkagnici; A Sargin; M Arslan; N Danisman
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.